Lancet Respiratory Medicine

Article	Citations
Savolitinib in NSCLC: progress in the MET exon 14 journey	548
Broad protection from SARS-CoV-2 variants without antigen matching	339
European Respiratory Society International Congress 2022	286
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress	273
Opioids bring peace to patients with IPF cough	260
Predatory publishers appear in PubMed (and your inbox)	260
Thoracentesis: an old story and some new sources	255
Chronic obstructive pulmonary disease: 10 years of precision-guided success	230
Correction to Lancet Respir Med 2024; 12: 129–40	226
Interstitial lung disease: a decade of progress and hope	219
The burden of tuberculosis in Libya	216
Rituximab for connective tissue disease-associated interstitial lung disease	212
Rethinking the role of procalcitonin in suspected sepsis	211
Major gaps in childhood pneumonia research priorities remain	209
US Senate committee investigates asthma inhaler prices	204
Video laryngoscopy is not the nemesis of direct laryngoscopy	200
Predicted bodyweight—a misleading metric for tidal volume titration?	194
Chronic respiratory diseases in Asia: time for action	193
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis	192
Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop	192
Concerns regarding a suggested long COVID paradigm – Authors' reply	191
Impact of Myanmar's earthquake on respiratory health	187
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership	184
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study	180
First results from the international paediatric bronchiectasis registry (Child-BEAR-Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cros	176

FLiRTing with danger as SARS-CoV-2 variants evolve	171
Long COVID: systemic inflammation and obesity as therapeutic targets	169
Rheumatoid arthritis-associated interstitial lung disease: screening, diagnosis, and treatment—an expert group consensus statement	169
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis	168
Australia bans engineered stone to prevent silicosis	151
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials	143
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial	143
Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials	142
Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts	140
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis	137
Claudio Castanos—leader in cystic fibrosis care in Argentina	136
Sarcoidosis and fatigue: there is a useful cognitive treatment? – Authors' reply	136
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges	133
Solid and semi-solid perspectives in thoracic surgery	131
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta	127
Genetic associations and lung function in IPF: unexpected answers, persistent questions	127
Extracorporeal cardiopulmonary resuscitation: not why, but how	126
Trump administration decimates worker health oversight	121
Endotracheal surfactant for infants with life-threatening bronchiolitis (BESS): a randomised, blinded, sham-controlled, phase 2 trial	121
Correction to Lancet Respir Med 2021; 9: 1275–87	120
Correction to Lancet Respir Med 2022; 10: 972–84	120
Correction to Lancet Respir Med 2025; 13: 244–55	119
Non-invasive respiratory supports and criteria for intubation in randomised trials of acute hypoxaemic respiratory failure: a systematic review and network meta-analysis	117
Sphaerosymphony: turning air quality data into music	114
Precision-guided immunomodulatory therapy in sepsis	114
Association of SARS-CoV-2 infection and persistence with long COVID	112
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial	111
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, m	111
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial	110
Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts	110
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO	108
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study	106
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub	106
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis	103
Chronic cough as a disease: implications for practice, research, and health care	102
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials	102
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing s	102
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co	98
Health effects from climate-driven events: lessons learnt	97
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial	97
Spirometry in female individuals – Authors' reply	96
Choice overload for RSV prevention—how to form your opinion	95
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration	95
US lung cancer report suggests years of encouraging progress under threat from health agency cuts	93
Developments and priorities in bronchiectasis research	93
The Ramp to Nowhere: When hope slips through the cracks in care	93
Management after combined BPA and medical therapy in CTEPH: time for cardiopulmonary exercise testing	92
NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma	91
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO	83
COP27 Climate Change Conference: urgent action needed for Africa and the world	79

Underappreciated causes of obstructive lung disease	78
Liberal or restrictive transfusion for VV ECMO	77
Clean air, climate targets, and respiratory health in Europe	76
Pulmonary hydatid disease in children: a neglected burden hidden in plain sight	75
Correction to Lancet Respir Med 2023; 11: 1064–74	75
Russell Winwood: “COPD Athlete” defying views on lung disease	74
Pre-COPD: an evolving concept with practice potential	73
Unveiling a hidden phenotype of early tuberculosis	73
Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial	73
Trouble with promoting lung cancer screening in never-smokers	73
Prevalence of sleep-disordered breathing in an African general population: The Benin Society and Sleep (BeSAS) study	73
Real-time subphenotyping in acute respiratory distress syndrome: a step towards precision medicine	72
Opioid use and sleep apnoea	72
Realignment of clinical research after the COVID-19 era	70
Pulmonary fibrosis in chILD: bridging the gap	70
Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial	69
Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven ot	69
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials	69
Unavailability of varenicline: a global tragedy for the fight against the tobacco epidemic	68
Pooled testing for TB: revisiting a cost-saving innovation	67
Collateral caring	67
The recent explosion in snortable energy powder consumption	67
Early-life respiratory syncytial virus disease and long-term respiratory health	67
Treating acute respiratory illness: the need to be proactive	67
SIMPLIFYing cystic fibrosis treatment in a post-modulator era	66
A benchmarking study and roadmap for sepsis: who dies from septic shock?	66
COVID-19—an infectious disease in the top five causes of death in Australia	66
Society of Critical Care Medicine Critical Care Congress 2023	66
Assessing the reversibility of bronchiectasis with deep learning	66
US EPA backs industry lawsuit to undo its own work on air pollution rule	65
Combined SHP2 and KRASG12C inhibitor therapy in patients with non-small-cell lung cancer	63
Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PR	62
Wildfires in southern California: concerns for lung health	62
Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial	62
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial	61
Biological subphenotypes in severe acute hypoxaemic respiratory failure and acute respiratory distress syndrome using rapid prospective classification (SPARC) in the USA: a multicentre, observational,	60
RSV vaccination and immunisation programmes accelerating worldwide	60
Breathing barriers: bridging lung health, research, and awareness	60
Pioneering a paradigm shift in asthma management: remission as a treatment goal	59
Managing tuberculosis before the onset of symptoms	59
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial	59
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from tw	59
Where fresh air fails: COPD and the hidden burden of coastal living	58
Beyond the ventilator: rethinking daily evaluation of respiratory drive and effort	58
Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement	57
Core outcome measurement instruments for use in clinical and research settings for adults with post-COVID-19 condition: an international Delphi consensus study	57
Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial	57
Cryobiopsy versus conventional bronchoscopic sampling for peripheral pulmonary lesions (Cryo-RCT): an open-label, parallel-group, randomised trial	56
Correction to Lancet Respir Med 2026; 14: e51–52	56
Home monitoring in interstitial lung diseases	56
Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trial	55
Sanjay Ramakrishnan—several lucky turns to arrive at COPD	51
Trial emulation with observational data in cystic fibrosis	51
JCOG0802 and CALGB140503: the gap between trial design and clinical application	51
NUTRIREA-3: where to next?	51
Correction to Lancet Respir Med 2025; 13: 800–08	51
Cardiac and vascular serious adverse events following tixagevimab–cilgavimab	50
What is adequate preoxygenation? – Authors' reply	49
The importance of post-tuberculosis morbidity in high-income countries	49
EVEREST and the eosinophil paradox – Authors' reply	49
Rise in group A streptococcal infections in England	48
Moving forward in IPF: lessons learned from clinical trials	47
Non-invasive respiratory support improves outcomes in high-income countries	47
Common and rare variants and survival in idiopathic pulmonary fibrosis	47
Continuing ECMO with no possible transition to recovery or transplant	47
Continued enteral nutrition until extubation compared with fasting before extubation in patients in the intensive care unit: an open-label, cluster-randomised, parallel-group, non-inferiority trial	46
2026 GINA report for asthma	45
Rethinking bronchiectasis through a metabolic lens	44
Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multi	43
Tackling the global burden of lung disease through prevention and early diagnosis	43
Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies	42
FAK co-inhibition in KRASG12C-mutated non-small-cell lung cancer	42
General population-based lung function trajectories over the life course: an accelerated cohort study	42
Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled c	41
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicent	41
Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	41
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial	40
Remission in chronic cough: an achievable target?	40
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and	39
European Lung Cancer Congress 2024	38

Flavia Machado—a Latin American leader in sepsis	38
Use of lung-cancer trends for global and public health priorities	38
Stubble: the Farmer's Bane	38
Perioperative lung expansion and pulmonary outcomes after abdominal surgery	38
Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study	38
Guidelines might help reduce the burden of asthma in African children	37
US Senate announces planned gun reforms after latest school shooting	37
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO – Authors' reply	37
The upcoming influenza season and protection from vaccines	36
Neomi Shah—cracking the conundrum of sleep disorders	35
Chronic respiratory disease in Indigenous peoples: a framework to address inequity and strengthen respiratory health and health care globally	34
Community-acquired pneumonia: the best candidates for clarithromycin	34
Fighting sepsis: still a long way to go	33
Ventilation during surgery: moving away from one-size-fits-all	33
International guideline recommendations and eligibility criteria for home oxygen therapy	32
Patient in her 70s with COPD and asthma improving significantly since using monoclonal antibody dupilumab	32
Correction to Lancet Respir Med 2023; published online Feb 3. https://doi.org/10.1016/S2213-2600(22)00491-X	32
Reflections 5 years on from the approval of ETI therapy	31
ECMO: more than just a bridge over troubled waters?	31
Correction to Lancet Respir Med 2024; 12: 544–55	31
How early should CFTR modulators be initiated to prevent structural cystic fibrosis lung disease?	31
Surviving sepsis with multiple serious complications	31
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised,	30
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomi	30
Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management	30
Oral corticosteroids for acute preschool wheeze	30
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial	29
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial	29
When evidence is not enough: making videolaryngoscopy the default for tracheal intubation	29
Effect of non-invasive ventilation after extubation in critically ill patients with obesity in France: a multicentre, unblinded, pragmatic randomised clinical trial	28
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled,	28
Lifting the veil on humour and anaesthetics	28
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study	28
Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts	27
Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlle	27
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials – Authors' reply	26
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study	26
Management of prematurity-associated lung disease from infancy through to adulthood	26
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study	26
Concerns regarding a suggested long COVID paradigm	25
C-reactive protein-guided treatment in pneumonia: charting a personalised approach – Authors’ reply	25
Discussions on VT4COVID	25
Correction Lancet Respir Med 2022; 10: 937–48	25
The carbon footprint of inhaled medications in Australia	24
Correction to Lancet Respir Med 2025; 13: 318–26	24
Arrival of biosimilars in respiratory medicine: towards improved access to biologics for patients	23
Preoxygenation strategies for intubation: a closer look at inclusion criteria and patient heterogeneity – Authors' reply	23
The passage of Ireland's Human Tissue Act: challenges, consequences, and cross-border cooperation	23
Unseen collateral damage: tackling preventable morbidity and mortality in family members of ICU decedents	23
Continued resuscitation at the scene versus early transport for refractory out-of-hospital cardiac arrest	23
Lockdown as the mother of invention: disruptive technology in a disrupted time	23
Remdesivir saves lives. Were 3 years needed to learn that?	23
High-dose rifampicin to treat tuberculosis infection: potential and pitfalls	23
Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?	22
Outcome predictors and patient progress following delivery in pregnant and postpartum patients with severe COVID-19 pneumonitis in intensive care units in Israel (OB-COVICU): a nationwide cohort study	22
Home-based monitoring in chronic respiratory diseases: in search of Panacea	22
How Glasgow's 1957 tuberculosis screening programme could help countries today	22
Air pollution, climate change, and lung health in Europe	22
US EPA strengthens PM2·5 air pollution limits	22
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 tria	21
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial	21
Neurofilament light chain in post-cardiac arrest prognostication: from signal to strategy	21
Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome	21
Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX): a multicentre, randomised, sham-controlled trial	21
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis	20
Confounding undermines inferences of preventive therapy effectiveness among subgroups of tuberculosis contacts	20
Concerning the use of aminoglycosides in ventilator-associated pneumonia – Authors' reply	20
Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial	20
Living with spinal muscular atrophy while working in critical care	20
D-dimer thresholds in pulmonary embolism: avoiding one-size-fits-all	19
Phenotypes of idiopathic pulmonary arterial hypertension	19
Addressing the origins and health effects of small lungs	19
European Respiratory Society International Congress 2024	19
Treatment strategy for EGFR mutated NSCLC	19
Tuberculosis, conflict, and displacement	19
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study	19
Can the positive findings from POD1UM-304 improve patient care worldwide?	19
Trouble with promoting lung cancer screening in never-smokers – Authors' reply	19
Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, rando	19
Add-on LAMA therapy in asthma: an underused strategy for exacerbation prevention	18
Implementing endotoxin adsorption for septic shock into clinical practice	18
Opportunities and challenges of COPD tertiary prevention	18
Sedative medications: an avoidable cause of asthma and COPD exacerbations?	18
What is next for BCG revaccination to prevent tuberculosis?	17
Navigating uncertainty: asthma biologics during pregnancy	17
Chronic obstructive pulmonary disease: new therapies and old needs	17
Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials	17
Idiopathic inflammatory myopathies related lung disease in adults	17
Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort study	17
Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise	16
FEF25–75% trajectories from age 7 to 53 years, associations with childhood and parental preconception factors, and midlife COPD risk: a prospective cohort study	16
Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study	16
The future of paediatric acute respiratory distress syndrome	16
Systematic endoscopic staging of mediastinum in locally advanced NSCLC: a SEISMIC change?	16
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open	16